Esha Jain

Esha Jain

Auto-generated profile, based on publicly available information

Esha Jain

Department of Molecular Biology, Massachusetts General Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Cell
Verified
Journal Article
Closed access
DSDavid B. Sykes
David B. Sykes
YKYoumna S. Kfoury
Youmna S. Kfoury
FMFrançois E. Mercier
François E. Mercier
MWMathias J. Wawer
Mathias J. Wawer
JLJason M. Law
Jason M. Law
DSDavid T. Scadden
David T. Scadden

1 March 2020 in Annals of Oncology
Verified
Journal Article
Closed access
RBR. Barroso-Sousa
R. Barroso-Sousa
EJE. Jain
E. Jain
OCO. Cohen
O. Cohen
DKD. Kim
D. Kim
JBJ. Buendia-Buendia
J. Buendia-Buendia
NWN. Wagle
N. Wagle

10 February 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CPCorrie A. Painter
Corrie A. Painter
EJEsha Jain
Esha Jain
BTBrett N. Tomson
Brett N. Tomson
MDMichael Dunphy
Michael Dunphy
RSRachel E. Stoddard
Rachel E. Stoddard
NWNikhil Wagle
Nikhil Wagle

1 June 2016 in Cell
Verified
Journal Article
Closed access
SKSita Kugel
Sita Kugel
CMCarlos Sebastián Muñox
Carlos Sebastián Muñox
JFJulien Fitamant
Julien Fitamant
KRKenneth N. Ross
Kenneth N. Ross
SSSupriya K. Saha
Supriya K. Saha
RMRaul Mostoslavsky
Raul Mostoslavsky

4 February 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
TKTanya E. Keenan
Tanya E. Keenan
SPSonia Pernas
Sonia Pernas
PEPedro Exman
Pedro Exman
EJEsha Jain
Esha Jain
STSara M. Tolaney
Sara M. Tolaney
Purpose: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and PTEN alterations, defined as nonsynonymous mutations or 1 or 2 copy deletions, were associated with clinical benefit to anti-PD-1/L1 therapy in mTNBC. Experimental Design: We identified patients with mTNBC, who consented to targeted DNA sequencing and were treated with ICIs on clinical trials between April 2014 and January 2019 at Dana-Farber Cancer Institute (Boston, MA). Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were correlated with tumor genomic features. Results: Sixty-two women received anti-PD-1/L1 inhibitors alone (23%) or combined with targeted therapy (19%) or chemotherapy (58%). High TMB (18%) was associated with significantly longer PFS (12.5 vs. 3.7 months; P = 0.04), while PTEN alterations (29%) were associated with significantly lower ORR (6% vs. 48%; P = 0.01), shorter PFS (2.3 vs. 6.1 months; P = 0.01), and shorter OS (9.7 vs. 20.5 months; P = 0.02). Multivariate analyses confirmed that these associations were independent of performance status, prior lines of therapy, therapy regimen, and visceral metastases. The survival associations were additionally independent of PD-L1 in patients with known PD-L1 and were not found in mTNBC cohorts treated with chemotherapy (n = 90) and non-ICI regimens (n = 169). Conclusions: Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and PTEN alterations were associated with longer and shorter survival, respectively. These observations warrant validation in larger datasets.

1 March 2016 in Molecular Cell
Verified
Journal Article
Closed access
SBSyed I.A. Bukhari
Syed I.A. Bukhari
STSamuel S. Truesdell
Samuel S. Truesdell
SLSooncheol Lee
Sooncheol Lee
SKSwapna Kollu
Swapna Kollu
ACAnthony Classon
Anthony Classon
SVShobha Vasudevan
Shobha Vasudevan